Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A primary care study of tailored advice for stopping smoking
Source of recordUK Trials
ISRCTNISRCTN05385712
Date ISRCTN assigned14/02/2008
Local reference number(s)BRD/06/022
Public titleA primary care study of tailored advice for stopping smoking
Scientific titleEffectiveness of computer tailored Smoking Cessation Advice in Primary carE: a randomised trial
AcronymESCAPE
Disease/condition/study domainSmoking cessation
Study hypothesisPersonally tailored feedback reports, based on an assessment of individual needs and tailored to levels of reading ability, sent to smokers identified from general practitioner (GP) lists with varying levels of motivation and readiness to quit, will increase quit rates and quitting activity over and above that found with standard self help and usual care received from the practice.

The study objectives are:
1. To compare the effectiveness of sending personalised computer tailored feedback reports to smokers with sending standard self-help materials
2. To explore the effectiveness of tailored feedback reports by socio-economic status to determine their effect in more deprived groups
3. To determine the characteristics of smokers who are prompted to change their behaviour after receiving tailored feedback reports

Please note that the pilot study to this randomised trial was assigned an ISRCTN in 2004. This was assigned to ISRCTN34254423: Pilot trial to assess the feasibility and response rates for an RCT evaluating the effectiveness of a computer tailored intervention for smoking cessation in general practice (see http://www.controlled-trials.com/ISRCTN34254423).
Design/methodologyRandomised, single centre, controlled trial
Research ethics reviewEthics approval received from the Northern and Yorkshire Multicentre Research Ethics Committee (MREC) on the 19th April 2006 (ref: 06/MRE03/10).
Countries of trialUnited Kingdom
Participants - inclusion criteriaAll current cigarette smokers aged 18 to 65, either sex, able to read English will be eligible for inclusion in the study.
Participants - exclusion criteriaExclusion criteria are minimal because the aim is to recruit all smokers. However, any patients selected who are considered by the GP to be unsuitable for the project, e.g., people with severe mental impairment or severely or terminally ill, will be excluded.
Patient information material
Anticipated start date01/07/2007
Anticipated end date31/12/2008
Status of trialOngoing
Target number of participants7250
InterventionsThe control group will receive the usual care plus standard information. Participants will be assessed at baseline and sent standard non-tailored information (NHS Smokefree booklet), as well as receiving the usual care offered by their general practice. The control group receive only one mailing on receipt of their completed baseline questionnaire.

The intervention group will receive usual care plus standard information plus computer-tailored feedback reports based on the information obtained at baseline. The intervention group receives an additional assessment and personal report one month after the baseline.

The follow up is 6 months after baseline.
Primary outcome measure(s)Prolonged abstinence for 1 month and for 3 months at the 6-month follow-up.

Outcomes will be measured by postal questionnaire. Non-respondents to questionnaires will receive one postal reminder. Non-respondents to the reminder will be contacted by telephone. In order to estimate the accuracy of self-reports, a random sample of 20% of the participants who report abstinence will have their status validated by salivary cotinine sample, obtained by post.
Secondary outcome measure(s)1. 24 hour and 7 day point-prevalence abstinence
2. Quit attempts
3. Changes in motivation and intention to quit
4. Cognitions measured at baseline
5. Use of Nicotene Replacement Therapy (NRT) or Zyban
6. Any contact with advice services or health professionals (group, clinic, telephone, or face-to-face)
7. Use of NHS resources and other smoking cessation aids for economic analysis

Process measures:
1. Adherence to advice
2. Perceptions of the feedback reports
3. Perceived personal relevance of the feedback reports

Information from General Practices:
Performance against target figures set by PCTs before and after the intervention as indicators of activity
Sources of fundingCancer Research UK (CRUK) (UK) (ref: C16265)
Sponsor nameUniversity College London (UCL) (UK)
Sponsor detailsHamstead Campus
Rowland Hill Street
London
United Kingdom
NW3 2PF
Sponsor telephone+44 (0)20 7794 6329
Sponsor emailo.avwenagha@medsch.ucl.ac.uk
Sponsor websitehttp://www.ucl.ac.uk/
Contact nameDr Hazel Gilbert
Contact detailsDepartment of Primary Care and Population Sciences
University College London (UCL)
Hamstead Campus
Rowland Hill Street
London
United Kingdom
NW3 2PF
Contact telephone+44 (0)20 7317 7548
Contact emailhazel.gilbert@ucl.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN05385712
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central